clinical trial · NCT05881993
Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects
Comanche Biopharma·early phase1·completed·n = 45
Healthy Volunteer StudyCBP-4888Placebo
brief summary
This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.
started
May 22, 2023
primary completion
May 22, 2024
completion
May 22, 2024
last updated
Sep 26, 2025
detailed description
This study will involve female subjects meeting all inclusion criteria and no exclusion criteria. Cohorts of CBP-4888 are planned to be investigated in a sequential dose-escalation manner. Each cohort of subjects will be randomized to CBP-4888 to placebo and administered a single subcutaneous dose.
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-4888 in Healthy, Non-Pregnant Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol